CL2020002050A1 - Nemolizumab en el tratamiento de dermatitis atópica con excoriación moderada a grave - Google Patents
Nemolizumab en el tratamiento de dermatitis atópica con excoriación moderada a graveInfo
- Publication number
- CL2020002050A1 CL2020002050A1 CL2020002050A CL2020002050A CL2020002050A1 CL 2020002050 A1 CL2020002050 A1 CL 2020002050A1 CL 2020002050 A CL2020002050 A CL 2020002050A CL 2020002050 A CL2020002050 A CL 2020002050A CL 2020002050 A1 CL2020002050 A1 CL 2020002050A1
- Authority
- CL
- Chile
- Prior art keywords
- atopic dermatitis
- treatment
- nemolizumab
- excoriation
- moderate
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
En la presente memoria se revelan métodos para el tratamiento selectivo de la dermatitis atópica (AD) en un sujeto que tiene excoriaciones de la piel, composiciones farmacéuticas para su uso en el tratamiento de la dermatitis atópica en un sujeto que tiene excoriaciones de la piel, usos de nemolizumab o un equivalente en la fabricación de un medicamento para el tratamiento de la dermatitis atópica en un sujeto que tiene excoriaciones de la piel, y métodos para la identificación de un sujeto que tiene dermatitis atópica que es probable que responda al tratamiento con nemolizumab o un equivalente del mismo.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862628714P | 2018-02-09 | 2018-02-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2020002050A1 true CL2020002050A1 (es) | 2020-12-11 |
Family
ID=65729402
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2020002050A CL2020002050A1 (es) | 2018-02-09 | 2020-08-07 | Nemolizumab en el tratamiento de dermatitis atópica con excoriación moderada a grave |
Country Status (15)
Country | Link |
---|---|
US (1) | US20200385476A1 (es) |
EP (1) | EP3749353A1 (es) |
JP (2) | JP2021512917A (es) |
CN (1) | CN112040976A (es) |
AU (1) | AU2019219608A1 (es) |
BR (1) | BR112020016144A2 (es) |
CA (1) | CA3090062A1 (es) |
CL (1) | CL2020002050A1 (es) |
IL (1) | IL276524A (es) |
MX (1) | MX2020008193A (es) |
PH (1) | PH12020551185A1 (es) |
RU (1) | RU2758378C1 (es) |
SG (1) | SG11202007558YA (es) |
TW (1) | TW201941800A (es) |
WO (1) | WO2019155427A1 (es) |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
FR2761994B1 (fr) | 1997-04-11 | 1999-06-18 | Centre Nat Rech Scient | Preparation de recepteurs membranaires a partir de baculovirus extracellulaires |
EP1188830B1 (en) | 1999-06-02 | 2010-01-20 | Chugai Seiyaku Kabushiki Kaisha | Novel hemopoietin receptor protein ,nr10 |
EP1858924A1 (en) * | 2005-02-14 | 2007-11-28 | ZymoGenetics, Inc. | Methods of treating skin disorders using an il-31ra antagonist |
JP2010210772A (ja) | 2009-03-13 | 2010-09-24 | Dainippon Screen Mfg Co Ltd | 液晶表示装置の製造方法 |
RU2620071C2 (ru) * | 2010-11-17 | 2017-05-22 | Чугаи Сеияку Кабушики Каиша | Мультиспецифическая связывающая антиген молекула, которая обладает альтернативной функцией к функции фактора свертывания крови viii |
US8790651B2 (en) * | 2011-07-21 | 2014-07-29 | Zoetis Llc | Interleukin-31 monoclonal antibody |
CA2980992C (en) * | 2015-04-14 | 2024-01-23 | Akihisa Kaneko | Pharmaceutical composition for prevention and/or treatment of atopic dermatitis containing il-31 antagonist as active ingredient |
SG10202112628UA (en) * | 2015-11-30 | 2021-12-30 | Anacor Pharmaceuticals Inc | Topical pharmaceutical formulations for treating inflammatory-related conditions |
-
2019
- 2019-02-08 WO PCT/IB2019/051051 patent/WO2019155427A1/en unknown
- 2019-02-08 CN CN201980024489.7A patent/CN112040976A/zh active Pending
- 2019-02-08 EP EP19710488.8A patent/EP3749353A1/en active Pending
- 2019-02-08 RU RU2020129578A patent/RU2758378C1/ru active
- 2019-02-08 MX MX2020008193A patent/MX2020008193A/es unknown
- 2019-02-08 CA CA3090062A patent/CA3090062A1/en active Pending
- 2019-02-08 SG SG11202007558YA patent/SG11202007558YA/en unknown
- 2019-02-08 BR BR112020016144-6A patent/BR112020016144A2/pt unknown
- 2019-02-08 AU AU2019219608A patent/AU2019219608A1/en active Pending
- 2019-02-08 JP JP2020542801A patent/JP2021512917A/ja active Pending
- 2019-02-11 TW TW108104519A patent/TW201941800A/zh unknown
-
2020
- 2020-08-05 PH PH12020551185A patent/PH12020551185A1/en unknown
- 2020-08-05 IL IL276524A patent/IL276524A/en unknown
- 2020-08-07 CL CL2020002050A patent/CL2020002050A1/es unknown
- 2020-08-07 US US16/988,554 patent/US20200385476A1/en active Pending
-
2023
- 2023-09-21 JP JP2023155476A patent/JP2023182632A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
MX2020008193A (es) | 2020-11-24 |
RU2758378C1 (ru) | 2021-10-28 |
BR112020016144A2 (pt) | 2020-12-15 |
EP3749353A1 (en) | 2020-12-16 |
WO2019155427A1 (en) | 2019-08-15 |
TW201941800A (zh) | 2019-11-01 |
SG11202007558YA (en) | 2020-09-29 |
IL276524A (en) | 2020-09-30 |
PH12020551185A1 (en) | 2021-05-17 |
CA3090062A1 (en) | 2019-08-15 |
AU2019219608A1 (en) | 2020-08-27 |
JP2023182632A (ja) | 2023-12-26 |
CN112040976A (zh) | 2020-12-04 |
US20200385476A1 (en) | 2020-12-10 |
JP2021512917A (ja) | 2021-05-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2019001874A1 (es) | Inhibidores de tgfß1 isoforma-específicos contexto-permisivos y uso de los mismos. | |
CL2019003636A1 (es) | Polinucleótidos de aadc para el tratamiento de la enfermedad de parkinson. | |
CL2018001152A1 (es) | Composiciones y métodos para el tratamiento del cáncer | |
BR112017028413A2 (pt) | peptídeos antimicrobianos estabilizados | |
BR112017024384A2 (pt) | bactérias modificadas para reduzir hiperfenilalaninemia | |
CR20170014A (es) | Métodos para tratar el cáncer con inhibidores de tigit y agentes contra el cáncer | |
BR112017016772A2 (pt) | bactérias probióticas recombinantes para uso no tratamento de uma disfunção inflamatória da pele e método para tratá-la | |
PE20160949A1 (es) | Cepa aislada de clonostachys rosea para uso como agente de control biologico | |
CL2018000963A1 (es) | Cosmética que tiene bacterias probióticas | |
CL2016002794A1 (es) | Vacuna de péptido que comprende un péptido ras mutante y un agente quimioterapéutico | |
BR112018015367A2 (pt) | carreadores oromucosais de nanofibra para tratamento terapêutico | |
CL2020000220A1 (es) | Composiciones que comprenden aminoácidos para su uso en el tratamiento de enfermedades relacionadas con la disfunción mitocondrial. | |
BR112018001435A2 (pt) | métodos para entrega linfática de agentes ativos | |
BR112017006113A8 (pt) | usos de auristatina, composições farmacêuticas, formas de dosagem para o tratamento de câncer e kits. | |
CL2015002620A1 (es) | Derivados piridin-4-ilo | |
NI201600070A (es) | Inhibidores tetracíclicos de autotaxina | |
ECSP22038978A (es) | INHIBICIÓN DE INTEGRINA ALFA4ß7 HUMANA | |
DOP2016000170A (es) | Compuestos derivados de hidroxiformamida y usos del mismo | |
CO2017001626A2 (es) | Anticuerpo anti-orai1 | |
BR112017024908A2 (pt) | usos terapêuticos da 4-cloroquinurenina | |
ECSP16086247A (es) | (s)-pirlindole y sus sales farmacéuticamente aceptables para uso en medicina | |
AR113618A1 (es) | Péptidos antimicrobianos y métodos para usarlos | |
CO2023013465A2 (es) | Composiciones y métodos para inhibir cetohexoquinasa (khk) | |
CL2021000129A1 (es) | Apirasas solubilizadas, métodos y usos | |
CL2019000846A1 (es) | Proteína terapéutica. |